President of 23andMe, Andy Page, is to leave the company in December, according to a letter sent to employees by CEO Anne Wojcicki. It is unclear where he is going, but he will remain a board member. In his time at the company, Page scaled the consumer business and its management team, tripling its employee base to 23andMe, and growing its database of genetic information. Almost as soon as he arrived, he and Wojcicki had their hands full with a regulatory crisis, receiving a warning from the FDA that led to them discontinuing their direct-to-consumer testing kits.
President of 23andMe, Andy Page, is to leave the company in December, according to a letter sent to employees by CEO Anne Wojcicki. It is unclear where he is going, but he will remain a board member. In his time at the company, Page scaled the consumer business and its management team, tripling its employee base to 300, and growing its database of genetic information. Almost as soon as he arrived, he and Wojcicki had their hands full with a regulatory crisis, receiving a warning from the FDA that led to them discontinuing their direct-to-consumer testing kits.